Jesús Castilla, Óscar Lecea, Carmen Martín Salas, Delia Quílez, Ana Miqueleiz, Camino Trobajo-Sanmartín, Ana Navascués, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Nerea Egüés, Guillermo Ezpeleta, Carmen Ezpeleta
{"title":"2022年5月至7月西班牙纳瓦拉地区SARS-CoV-2抗体血清阳性率和COVID-19风险","authors":"Jesús Castilla, Óscar Lecea, Carmen Martín Salas, Delia Quílez, Ana Miqueleiz, Camino Trobajo-Sanmartín, Ana Navascués, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Nerea Egüés, Guillermo Ezpeleta, Carmen Ezpeleta","doi":"10.2807/1560-7917.ES.2022.27.33.2200619","DOIUrl":null,"url":null,"abstract":"<p><p>In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389855/pdf/","citationCount":"10","resultStr":"{\"title\":\"Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.\",\"authors\":\"Jesús Castilla, Óscar Lecea, Carmen Martín Salas, Delia Quílez, Ana Miqueleiz, Camino Trobajo-Sanmartín, Ana Navascués, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Nerea Egüés, Guillermo Ezpeleta, Carmen Ezpeleta\",\"doi\":\"10.2807/1560-7917.ES.2022.27.33.2200619\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.</p>\",\"PeriodicalId\":520613,\"journal\":{\"name\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389855/pdf/\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2022.27.33.2200619\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2022.27.33.2200619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
